ATYR · aTYR PHARMA INC · Metrics
Market Cap
$17.33M
Shares
98.09M
Volume · Oct 21
909.09K
Avg daily vol (3M)
3.24M
ATYR metrics
73 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.17
Market cap
$17.37M
Price action
20 metricsPrice change (1W)
-13.8%
Price change (30D)
-53.5%
Price change (3M)
-64.3%
Price change (6M)
-79.0%
Price change (YTD)
-77.9%
Price change (1Y)
-83.0%
Trailing year
Price change (5Y)
-98.0%
52-week high
$1.05
52-week low
$0.17
Change from 52-week high
-83.5%
Change from 52-week low
+0.9%
Annualized volatility
107.0%
Annualized volatility (3M)
69.8%
Beta
2.5
RSI (14D)
14.9
Price vs SMA 50
-55.8%
Price vs SMA 200
-72.4%
Avg volume (3M)
3.24M
Relative volume
0.4
Average dollar volume
$1.11M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
98.09M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
91.4×
reciprocal yield 1.1%
P / book
0.4
reciprocal yield 280.9%
FCF yield
-315.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-350.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-03-13
Profitability
9 metricsGross margin
—
Operating margin
-40,856.3%
Trailing 12 months
Net margin
-39,009.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$63.86M
Net income (TTM)
−$60.81M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-19.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$190,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.8%
Year over year · more shares
Revenue CAGR (3Y)
-73.7%
Revenue CAGR (5Y)
-55.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-124.6%
Return on assets
-87.1%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
−$63.20M
Free cash flow (TTM)
−$54.82M
Quick ratio
5.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$16.16M
Total assets
$69.83M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$54.54M
Capital expenditures (TTM)
$279,000
R&D (TTM)
$47.09M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
92
13F filer change QoQ
-21
Institutional ownership
40.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
15.7%
Private-fund adviser ownership
12.6%
Active holders' share change QoQ
-24.8%
Holder tenure
12.6
Price vs estimated holder cost
-27.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
7.1%
Short interest
3 metricsShort interest
13.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
52 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—